Dr. Emanual Michael Maverakis, MD

Dr. Maverakis practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Maverakis' NPI, 1942274592, was assigned on February 13, 2006. Dr. Maverakis graduated from Harvard Medical School in 2003. Dr. Maverakis holds California license A91555.

Dr. Maverakis' primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Maverakis' primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Maverakis to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maverakis practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Maverakis' primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Maverakis is board certified in dermatology by the American Board of Dermatology. Dr. Maverakis is licensed in California.

Dmand AI lists benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, hives, itchy rashes, minor injury to a limb, psoriasis and rash among the conditions Dr. Maverakis treats.

CMS data shows 1,452 Medicare services from Dr. Maverakis across 10 procedure codes in 2024, for 261 Medicare patients. Medicare paid $50,934 for them. Every service was in an office.

CMS counts 261 Medicare patients who saw Dr. Maverakis in 2024. The largest group is 65 to 74, with 101 patients. 71% of them have high cholesterol, and 69% have high blood pressure. 21% are also on Medicaid. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Maverakis' median patient age at 69, with 53% women.

In 2024, Dr. Maverakis wrote 957 Medicare Part D claims for 144 patients. 43% of them were for generic drugs. CMS names the drug for 797 of them, across 26 drugs with 11 or more claims each, at $3,789,509 in total drug cost. In 2023, CMS named 774 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Maverakis for performance year 2024, reported as part of a group. Dr. Maverakis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Maverakis as offering telehealth. CMS counts 357 procedures of removal of skin lesions by Dr. Maverakis, more than 83% of the clinicians it reports for that procedure.

Lower limb (leg) arthroscopy (minimally invasive joint repair): 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 227 papers to Dr. Maverakis, published from 2003 to 2025. 2019 was the busiest year, with 22. The most frequent topics are Psoriasis, Skin and Cytokines. Dr. Maverakis has published most often in JAMA Dermatol. Dr. Maverakis' most frequent co-authors are Stephanie T. Le, MD, Michelle Yaolin Cheng and Siba Prasad Raychaudhuri, MD.

Dmand AI links Dr. Maverakis to 13 clinical trials, 4 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Dermatitis, Atopic, Eczema and Alopecia Areata. University of California, Davis sponsors the most, 7. Open Payments lists research payments to Dr. Maverakis that name 3 trials.

CMS Open Payments shows 158 general payments to Dr. Maverakis from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 74% of the total. Abbvie Inc. paid the most, $31,153. It also lists 10 research payments totaling $9,254 from 2018 to 2022, naming 3 clinical trials.

Dmand AI lists 2 awards for Dr. Maverakis, most recently PECASE in 2011.

Dr. Maverakis graduated from Harvard Medical School in 2003. Dr. Maverakis is a member of American Association of Immunologists and AMA.

Dr. Maverakis is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.